GlassScriptPhysician profile
Alissa Welsh
NPI 1831509116
$8,881.54
in general payments reported to CMS, 2019-2025
34 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $966 · 2021: $1,185 · 2022: $1,027 · 2023: $1,488 · 2024: $1,123 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,816.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,809.17 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $924.12 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $889.31 | 2020-2025 | Cuvitru, Takhzyro, Elaprase |
| Glaxosmithkline, LLC. | $871.28 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $768.79 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Novartis Pharmaceuticals Corporation | $617.23 | 2019-2025 | |
| Grifols USA, LLC | $557.35 | 2019-2025 | Xembify, Gamunex-C |
| Regeneron Healthcare Solutions, INC. | $329.26 | 2019-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $281.67 | 2025 | Neffy |
| Pfizer INC. | $217.09 | 2019-2024 | |
| Kaleo, INC. | $156.78 | 2021-2023 | Auvi-Q |
| Optinose US, INC. | $151.04 | 2019-2023 | |
| Incyte Corporation | $140.71 | 2021-2024 | Opzelura |
| Blueprint Medicines Corporation | $137.34 | 2022-2025 | Ayvakit |
| Shire North American Group INC | $124.81 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols Shared Services North America, INC. | $123.16 | 2019 | |
| Genentech USA, INC. | $121.86 | 2025 | Xolair |
| Acclarent, INC | $107.64 | 2019 | |
| Organon LLC | $86.22 | 2025 | Vtama |
| Biocryst US Sales Co., LLC | $75.56 | 2022-2024 | Orladeyo |
| Amgen INC. | $63.46 | 2022-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $60.19 | 2024-2025 | Ryaltris |
| Octapharma USA, INC. | $38.48 | 2021 | |
| Pharming Healthcare, INC. | $37.83 | 2021-2023 | Ruconest |
| Cycle Pharmaceuticals INC | $28.13 | 2024-2025 | Sajazir |
| Teva Pharmaceuticals USA, INC. | $26.47 | 2021 | |
| Hospira, INC. | $22.34 | 2024 | |
| Arcutis Biotherapeutics, INC. | $20.69 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $19.09 | 2022 | |
| Leo Pharma INC. | $18.46 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.33 | 2021 | |
| Galderma Laboratories, L.P. | $14.48 | 2024 | |
| Phadia US INC. | $13.40 | 2024 | Immunocap |
| Alk-Abello, INC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alissa Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.